MULTIPLE MYELOMA

Early results from the MagnetisMM-6 trial reveal promising efficacy of elranatamab, daratumumab, and lenalidomide in treating newly diagnosed multiple myeloma.

Daratumumab effectively delays multiple myeloma relapse by monitoring minimal residual disease, offering hope for improved patient outcomes.

The IsKia trial reveals that isatuximab enhances MRD negativity in newly diagnosed multiple myeloma, especially in high-risk patients.

During a live event, Binod Dhakal, MD, and participants discussed their experience using selinexor in the second line and beyond in patients with multiple myeloma.

Cilta-cel therapy significantly enhances survival rates in lenalidomide-refractory multiple myeloma, outperforming standard treatments in recent trials.

The IRAKLIA study reveals that subcutaneous isatuximab offers comparable efficacy and improved patient satisfaction over intravenous administration for multiple myeloma.

Linvoseltamab plus bortezomib showed a manageable safety profile and 85% ORR in relapsed/refractory multiple myeloma, with few discontinuations.

During a live event, Konstantinos Sdrimas, MD, and community oncologists discussed patient concerns over CAR T-cell therapy toxicity and how to coordinate with CAR T providers.

During a live event, Samuel M. Rubinstein, MD, discussed the outcomes from the KarMMa-3 trial and real-world patients receiving ide-cel in terms of bridging therapy, quality of life, and prior BCMA therapy.

Combination therapy with BPd shows significant progression-free survival benefits in relapsed/refractory multiple myeloma patients with high-risk cytogenetic abnormalities.

During a live event, Taewoong Choi, MD, discussed the current state of therapy for transplant-ineligible newly diagnosed multiple myeloma.

JNJ-79635322 shows favorable responses and manageable safety in BCMA/GPRC5D-naïve patients with relapsed/refractory multiple myeloma.

Daratumumab enhances treatment efficacy in newly diagnosed multiple myeloma, showing improved MRD negativity and progression-free survival in recent clinical trials.

A phase 3 trial did not support a transplant-based approach for patients who already achieved MRD negativity or a tandem transplant approach for those who did not achieve prior MRD negativity.

A single cilta-cel infusion led to 33% of heavily pretreated relapsed/refractory multiple myeloma patients remaining progression-free at 5+ years.

Extended follow-up of MonumenTAL-1 shows talquetamab-tgvs yields durable ORRs and promising survival outcomes in relapsed/refractory multiple myeloma, with a tolerable safety profile.

During a live event, Konstantinos Sdrimas, MD, asked participants what community oncologists should consider when referring patients for CAR T-cell therapy.

During a live event, Samuel M. Rubinstein, MD, discussed the efficacy and safety outcomes from the KarMMa-3 trial.

During a live event, Naresh Bumma, MD, discussed CRS, oral and skin toxicities, and low discontinuation rates with talquetamab in multiple myeloma.

In a 6 to 2 vote, the Oncologic Drug Advisory Committee determined that findings from the phase 3 AQUILA trial do support a positive benefit-risk ratio for patients with smoldering multiple myeloma.

In an interview with Targeted Oncology, C. Ola Langren, MD, PhD, discussed the continuing impact of the groundbreaking FDA ODAC vote, the future of the Miami Myeloma MRD Meeting, and how researchers plan to continue expanding the role of MRD in myeloma and other hematologic malignancies.